Pilot Minimal Residual Disease in AML (Not Accredited)

 

The measurement of Minimal Residual Disease (MRD) populations is often performed following treatment for Leukaemic disorders. The levels of MRD are used as a predictive factor for relapse and as an indicator for patients entering remission. As such the measurement of MRD can have a direct effect on the treatment regimen of a patient.

 

The Minimal Residual Disease in AML programme will issue up to four send outs per financial year.  Each send out will include a reference sample and two follow up samples of a known AML case post treatment at different time points.

 

Participants will be asked to quantify the level of residual disease in the follow up samples. If you wish to be involved in the study please contact admin@ukneqasli.co.uk.    

 

No activities in relation to this EQA programme are subcontracted. 

 

Example Minimal Residual Disease in AML Report
To view the annotations on this report, please download the PDF and view in a PDF reader such as Adobe Acrobat.
MRD AML annotated.pdf
Adobe Acrobat document [664.1 KB]
Print Print | Sitemap

Follow Us Online!
Facebook Twitter LinkedIn Youtube

Disclaimer

Last updated 25th July 2017 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information, please click here.